By: IPP Bureau
Last updated : October 05, 2024 11:00 am
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Suven Life Sciences Ltd (Suven) announces five presentations covering clinical and pre-clinical assets from their portfolio of new chemical entities at the upcoming Neuroscience 2024 conference, taking place during October 5-9, 2024, in Chicago, Illinois, USA. Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN), will bring together neuroscientists from around the globe, representing leading Pharma, Biotech and Clinical Research institutes.
The presentation are:
- Ropanicant(SUVN-911),an α4β2n AChR Antagonist: A Phase-2 Study Evaluating the Safety and Efficacy in Participants with Moderate to Severe Major Depressive Disorder.
- Samelisant (SUVN-G3031): Safety and Efficacy Outcome from the Phase-2 Proof-of- Concept, Double-Blind, Placebo-Controlled Study in Patients with Narcolepsy.
- Rationale and Study Design for the Phase-3 Clinical Development Program of Masupirdine (SUVN-502), a Pure 5-HT6 Receptor Antagonist, for the Treatment of Agitation in Patients with Dementia of Alzheimer’s Type.
- Dual 5-HT1A and 5-HT2A Receptor Ligand SUVN-2206043 shows Antipsychotic and Antidepressant Like Effects in Animal Models.
- SUVN-L3307032, a Positive Allosteric Modulator(PAM) at Muscarinic M4 Receptor for the Treatment of Psychotic Symptoms.
Suven has 7 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study completed; pivotal Phase-3 study in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Placebo-controlled Phase-2b study in planning); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study initiated) and 2 other compounds in early stages of clinical development. In addition to these clinical assets, we have 6 projects in the research pipeline across multiple potential indications. Suven owns all intellectual property rights for its assets in all major markets.